Celgene Corporation

Aventis Pharmaceuticals Inc.

Garth E Ringheim

Gregory H Merriman

Daniel Gerard McGarry

Alexandre Gross

Patrick Shum

David Rampe

Jeffrey Stephen Sabol

Liang Ma

Francis A Volz

Peter Henry Schafer

Henry Chan

Roli Khattri

Monica Leung

Eun Mi Hur

Daniel G Mcgarry

Alexandre 245 Eighth Street Gross

Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

Methods of treating vitiligo using PD-1 binding antibodies

Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

Methods of treating psoriasis using PD-1 binding antibodies

The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R, R, R, R, R, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.

Heterocyclic compounds as P2X7 ion channel blockers

Growing community of inventors

Belle Mead, NJ, United States of America

Garth E Ringheim